[Sinovac Biotech Cures Nasdaq Filing Deficiency BEIJING, December 1, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA)(the “Company” or “Sinovac”), a leading provider of biopharmaceutical products in China, announced today that it has received a Nasdaq Staff letter indicating that the Form 20-F]
[Sinovac Biotech Cures Nasdaq Filing Deficiency BEIJING, December 1, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA)(the “Company” or “Sinovac”), a leading provider of biopharmaceutical products in China, announced today that it has received a Nasdaq Staff letter indicating that the Form 20-F]
[Sinovac Reports Unaudited First Half of 2017 Financial Results BEIJING, China, December 1, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that it reported its unaudited financial results]
[Sinovac Biotech Announces Update on Nasdaq Matters BEIJING, November 30, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA)(the “Company” or “Sinovac”), a leading provider of biopharmaceutical products in China, announced today that the Nasdaq Hearings Panel (the “Panel”) granted the Company’s ]
[Sinovac Biotech Announces Update on Nasdaq Matters BEIJING, November 30, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA)(the “Company” or “Sinovac”), a leading provider of biopharmaceutical products in China, announced today that the Nasdaq Hearings Panel (the “Panel”) granted the Company’s ]
[Sinovac Files 2016 Annual Report on Form 20-F and Reports Unaudited Fourth Quarter 2016 Financial Results Fourth Quarter 2016 Financial highlights Ÿ Quarterly sales from continuing operations were $31.4 million compared to $23.0 million in the prior year period, an increase of 36.7%. Sales increased]
[Sinovac Files 2016 Annual Report on Form 20-F and Reports Unaudited Fourth Quarter 2016 Financial Results Fourth Quarter 2016 Financial highlights Ÿ Quarterly sales from continuing operations were $31.4 million compared to $23.0 million in the prior year period, an increase of 36.7%. Sales increased]
[] [List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Sinovac Biotech Co., Ltd., a PRC company 3. Sinovac Research and Development Co., Ltd. (formerly known as Beijing Sinovac Biological Technology Co., Ltd.), a PRC company 4. Sinovac (Dalian) Vaccine Technology Co., Lt]
[] [List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Sinovac Biotech Co., Ltd., a PRC company 3. Sinovac Research and Development Co., Ltd. (formerly known as Beijing Sinovac Biological Technology Co., Ltd.), a PRC company 4. Sinovac (Dalian) Vaccine Technology Co., Lt]
[FORM 10-Q (Mark One) ☒ September 30, 2017 For the quarterly period ended: Or ☐ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Nu]
